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Abstract 
 
AIM: To evaluate the use of intravitreal dexamethasone as adjunctive therapy in the 
treatment of presumed bacterial endophthalmitis. 
 
DESIGN: Prospective randomised placebo-controlled clinical trial. 
 
METHODS: All patients with suspected endophthalmitis were divided into 3 groups; 
post cataract surgery (PC), bleb related endophthalmitis (BRE), and other (O) 
including endogenous, trauma and post vitreo-retinal surgery. All patients requiring 
vitrectomy or suspected to have fungal endophthalmitis were excluded. Within each 
group, patients were randomly assigned by pharmacy to receive intravitreal 
ceftazidime (2.225mg/0.1ml), vancomycin (1mg/0.1ml) and either dexamethasone 
(0.4mg/0.1) or placebo using masked labels. All vitreous biopsies and aqueous 
samples were sent for microbiological analysis. Patients were evaluated and if 
deemed necessary the injections were repeated after 48 hrs. Snellen visual acuity was 
measured on presentation, within the first 14 days post injection, and at 2-4 months 
as the primary outcomes measure. 
 
RESULTS:  62 patients were recruited and completed the protocol from 2001 to 
2005. 30 patients received intravitreal dexamethasone and 32 received intravitreal 
placebo. Preliminary analysis reveals no statistically significant difference in the 
visual acuity outcomes of either group with an average of 2.79 Snellen lines 
improvement of the intravitreal dexamethasone group versus 1.8 lines improvement 
of the placebo group. However subgroup analysis suggested a clinical trend to better 
visual acuity in the Post Cataract Steroid Subgroup with average of 4.1 lines 
improvement versus 2.7 in the placebo group (p =0.33). No adverse events 
attributable to the dexamethasone were reported. 
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CONCLUSIONS: Intravitreal dexamethasone appears safe and may be of benefit in 
post cataract presumed bacterial endophthalmitis. 
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Chapter 1: 
Introduction and Literature Review 
 
Endophthalmitis is defined as inflammation of the contents or cavity of the eye and 
usually represents an infection of the vitreous, although it may represent sterile 
inflammation. 
  
It may be divided into endogenous and exogenous depending on the source of the 
infection. In endogenous or metastatic endophthalmitis the bacteria have spread 
haematologically from an infective site elsewhere in the body to the eye. Sites of 
infection often include septic meningitis, endocarditis, pneumonia, osteitis etc. In 
exogenous endophthalmitis the infection has breached the outer structure of the eye 
in order to enter and infect the cavity of the eye. Exogenous can further be classified 
into its various causes: post cataract surgery, post penetrating trauma, post glaucoma 
surgery or other intraocular surgery, and spread from other infection such as keratitis 
or sinusitis. 
 
The causative organism can be bacterial, viral, fungal or protozoal. The most 
common bacteria in post cataract surgery are gram positive (60%) such as 
Staphlococcus epidermidis, Staphlococcus aureus, Streptococcus species, as well as 
gram negative (30%) such as Proteus and Pseudomonas species. The most common 
bacteria in endophthalmitis following glaucoma surgery include Haemophilus 
species and Streptococcus species 1. 
 
Once the structural integrity of the eye has been breached the sensitive intraocular 
structures are very vulnerable to both the infective organism, its toxins as well as the 
inflammatory response. The neural retina is particularly sensitive to toxins while the 
vitreous is particularly prone to long-term fibrosis resulting in tractional retinal 
detachments. 
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Therefore since both the infective organism as well as the subsequent immune 
response is thought to be pivotal in the disease process, it has been theorised that any 
effective treatment should aim at treating both arms of the pathological process. 
Hence intravitreal antibiotic injections are the mainstay of treatment. However, the 
role of any steroid either orally or intravitreally has been debated in the literature 
again and again. It was first experimented with as far back as 1974 2.The advantages 
of adding the intravitreal steroid at the time of intravitreal antibiotics is to provide a 
high anti-inflammatory concentration at the pathological site and limit systemic side 
effects especially in our typical elderly patient profile and in diabetic patients.  
 
This adjunctive use of intravitreal steroids needs to be proven as a safe and effective 
form of adjunctive therapy, before justifying changing our current use of intravitreal 
antibiotics alone. 
 
 
 
Figure 1. Post Cataract Endophthalmitis 
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A Pubmed, Medline, Ovid and ScienceDirect search of the literature reveals that the 
issue of using intravitreal steroid as adjunctive therapy is still controversial. Most 
authors seem to be of the opinion that steroids reduce inflammation, but as yet, no 
one has shown a clinically significant difference in the visual outcome and hence no 
standard accepted regime is in use. A survey, performed over 12 months from 
October1999 to September 2000, of all post cataract endophthalmitis in the United 
Kingdom 3 showed that of the 213 patients, only 17% received intravitreal steroids 
while Moorfields Eye Hospital 4 reported their routine use of oral steroids on day 
one and others report the use of subconjunctival steroids. This demonstrates the wide 
clinical practice within one country. The Bascom Palmer Eye Institute in Florida 5 
reported their 10 year post cataract surgery endophthalmitis experience in which they 
report their standard initial management consists of intravitreal vancomycin, 
ceftazidime and intravitreal dexamethasone. Other authors such as Chaudhry 6 in 
Connecticut reported their standard treatment includes intravitreal antibiotics and 
subconjunctival steroids. This again highlights the wide spectrum of clinical 
practice. This scope of practice reflects the lack of clear guidelines from the 
literature. 
 
In 2002 Elder and Mortlett 7 gave a very useful summary of the evidence for and 
against the use of steroids under the title “Clinical Controversy”. In essence they 
mention there have been six rabbit studies that have shown a benefit in reducing the 
inflammation and four rabbit studies showing no significant benefit. They mention 
three clinical trials. The most significant is that of Das et al 8, which was a 
prospective randomised clinical trial treating 63 cases of endophthalmitis with 
vitrectomy, intravitreal antibiotics and then either intravitreal dexamethasone or 
placebo. They showed a reduction in inflammation, but no independent influence on 
visual outcome. Elder and Mortlett concluded that there was no clear evidence either 
for or against the adjunctive use of intravitreal steroids. 
 
Other authors have reported differing results. Shah et al 9 in 2000 reported a 
retrospective nonrandomized comparative trial of 57 postoperative endophthalmitis 
cases comparing those who received intravitreal steroids to those who received only 
intravitreal antibiotics. They concluded that those who received steroids had a 
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significantly reduced likelihood of obtaining a 3-line improvement and felt this 
provided no support for the routine use of intravitreal steroids. 
 
Also in 2004 Pollack et al 10 attempted to demonstrate the use of intravitreal 
dexamethasone on its own to reduce intraocular inflammation in experimental 
Bacillus cereus endophthalmitis in 36 rabbit eyes. The rabbits were randomised to 
receive intravitreal Bacillus with or without intravitreal dexamethasone. They 
concluded that a standard dose of intravitreal dexamethasone does not appear to 
attenuate the intraocular inflammatory response and suggested alternative options 
such as vitrectomy to reduce the endotoxin load. 
 
The most recent randomised trial by Gan et al 11 reported in December 2005 is a 
prospective randomised placebo controlled clinical trial of 29 postoperative 
endophthalmitis cases, who received either intravitreal dexamethasone (13/29) or 
placebo (16/29) in addition to the intravitreal antibiotics. Their small study 
demonstrated a trend towards a better visual acuity in the dexamethasone group. This 
is the first study to demonstrate such a finding, justifying further investigation. 
 
In 2006 Pathengay et al 12 from India, reported the use of intravitreal triamcinolone 
acetonide for bacterial endophthalmitis as an interventional pilot case series. 
Triamcinolone is known to remain active in the vitreous for up to three months. They 
treated five patients with culture positive bacterial endophthalmitis with intravitreal 
antibiotics and then after 48-72 hrs injected intravitreal triamcinolone. All patients 
also received oral ciprofloxacin. In all five cases they reported complete resolution 
of the inflammation, which suggested a beneficial response to intravitreal steroids. 
 
In 2007 Ermis et al 13 reported on the use of intravitreal moxifloxacin with and 
without intravitreal dexamethasone in a randomised rabbit model of Staphylococcus 
aureus endophthalmitis and compared the outcomes with those of a control group as 
well as to a group receiving only intravitreal vancomycin. They concluded that all 
three treatment options were comparable. 
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 Rehak et al 14 in 2007 reported a six-year experience with postoperative 
endophthalmitis in which 32 of 34 patients underwent immediate vitrectomy, 
intravitreal antibiotics as well as intravitreal steroids. They concluded that immediate 
vitrectomy with intravitreal steroids and antibiotics resulted in good visual outcomes 
in 79% of cases. They also mentioned that systemic steroids seemed to be associated 
with a better final visual acuity. 
 
Saleh et al 15 in 2008 reported the potential advantage of early intravitreal 
dexamethasone specifically in Staphylococcus epidermidis endophthalmitis, but 
again concluded that a randomised clinical trial is still required. 
 
De Kasper et al 16 reported in 2008 on a trial of induced Staphlococcus aureus 
experimental endophthalmitis in rabbits. They were randomised to receive 
intravitreal vancomycin, amikacin and either placebo or dexamethasone. They 
demonstrated reduced clinical inflammation, improved ERG readings and reduced 
histological inflammation in the group receiving both antibiotics and 
dexamethasone. Again confounding the interpretation is the routine use of 
intravenous imipenem for four days and small numbers with only five in each group. 
The results of this study suggest that further investigation is warranted. 
 
In 2008 Liu et al 17 reported an experimental Bacillus endophthalmitis in rabbits 
where the rabbits were divided into two groups, each injected with Bacillus colonies 
and then 24 hours later divided into intravitreal balanced salt solution and intravitreal 
antibiotic group versus intravitreal dexamethasone and intravitreal antibiotics. They 
reported significant reduction in inflammatory scores, including histology, in the 
group receiving intravitreal dexamethasone. 
 
The dose of intravitreal dexamethasone seems to have become standardised since the 
report of Kwak et al 18 in 1992 which histologically suggested increasing 
disorganisation of the Muller cells at doses above 440 micrograms. 
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There have also been conflicting reports regarding the alteration of the 
pharmacodynamics of the antibiotics in the intravitreal injection by adding 
dexamethasone. Some reports initially suggested a decreased intravitreal 
concentration of vancomycin 19 while others have reported a decreased elimination 
of the intravitreal vancomycin 20. Most recently in 2005, Gan 21 reported no effect of 
intravitreal dexamethasone on the intravitreal concentration of vancomycin in a 
prospective trial of postoperative endophthalmitis. 
 
The role of immediate primary vitrectomy is also debated and the Endophthalmitis 
Vitrectomy Study in 199522 suggested that systemic antibiotics are not indicated and 
patients with visual acuity of perception of light or less fared better with immediate 
vitrectomy. Although techniques and instrumentation have improved, no randomised 
study has been repeated and this is often debated with some authors suggesting that 
any infective vitreous should always be removed surgically. 
 
Conclusion: 
From a review of the literature, it is difficult to come to a clear conclusion as to the 
benefit or otherwise of including intravitreal dexamethasone in the management of 
endophthalmitis. The constraints include the small sample sizes in most of the 
studies and the different treatment regimens used including vitrectomy, different 
antibiotics, different organisms etc.  
The only prospective randomised trial is that reported by Gan 11 et al, which showed 
a beneficial trend but no statistically significant difference because of the small 
sample size. 
There is merit in conducting another prospective randomised clinical trial, if only to 
provide additional data for a future meta analysis. 
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Chapter 2: 
Methods 
Study Design: 
A prospective randomised clinical trial comparing the adjunctive use of intravitreal 
dexamethasone versus placebo in addition to standard intravitreal antibiotics in 
presumed bacterial endophthalmitis was undertaken.  
  
Ethical Approval: 
Approval from the University Of Cape Town Research Ethics Committee, Faculty 
Of Medicine was formally granted on 09/02/2001 REC REF: 226/2000. Patients 
were recruited from January 2001 to December 2005. 
 
Participants: 
All patients with presumed bacterial endophthalmitis presenting to Groote Schuur 
Hospital were considered for inclusion. They were divided into 3 etiological groups 
by the admitting clinician: post cataract (PC), bleb related endophthalmitis (GB) and 
other (O), which included post penetrating injuries, metastatic endophthalmitis and 
post pars plana vitrectomy. This was to identify post cataract endophthalmitis as a 
priority subgroup, which could then be compared to other similar trials. 
 
Sample Size: 
It was planned to recruit 80-90 subjects over a five year period, of which about 35 
would be in the post cataract group. 
 
Exclusion Criteria: 
1. All patients with suspected fungal endophthalmitis. 
2. Patients with perception of light vision if the vitreo-retinal surgeons elected to 
perform a primary vitrectomy. Due to the lack of a full time vitreo-retinal surgeon at 
the time of the trial we could not always follow the Endophthalmitis Vitrectomy 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 14 
Study’s (EVS) 22 recommendation of performing an immediate primary vitrectomy if 
the vision was worse than hand movements. Therefore, patients were excluded if 
they underwent primary vitrectomy. 
 
Intervention: 
On presentation, patients were admitted, counselled, informed consent was obtained 
and intravitreal antibiotics and dexamethasone/placebo ordered. Pharmacy 
randomised the patients within the 3 groups using standard computer generated 
randomisation tables, to receive either dexamethasone 0.4mg/1ml together with the 
standard vancomycin 1mg/0.1ml and ceftazidime 2.225mg/0.1ml or placebo 0.1ml 
balanced salt solution. Penicillin allergic patients would receive amikacin 0.4mg/1ml 
in place of ceftazidime. A standard double-blinding label (dex/placebo) masked the 
dexamethasone/placebo injection so that both the surgeon and patient were unaware 
which drug was injected. Pharmacy kept the randomisation tables with the 
corresponding folder number until the end of the trial so that the clinicians at follow 
up would still be masked. When patients presented after hours a sealed envelope was 
given to the ward sister who mixed the steroid/placebo injection to keep the surgeon 
masked and pharmacy kept the correlating randomisation table numbers. 
 
Patients underwent standard vitreous biopsy as per surgeons’ preference with either 
local or general anaesthesia, with injection of the intravitreal antibiotics and 
dex/placebo injection. Vitreous and aqueous samples were sent for microbiological 
analysis and culture. A subconjunctival injection of vancomycin (25mg/0.5ml), 
ceftazidime (50mg/0.5ml) and celestone (1.5mg/0.5ml) was also administered at the 
end of the procedure.   
 
Injection Technique: 
The technique used was - 
Topical anaesthetic instilled 
5% betadine wash 
Lid speculum 
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Subconjunctival lignocaine injection for local anaesthetic cases. 
Anterior chamber tap (0.1 mls) with 23-gauge insulin syringe  
Transconjunctival vitreous tap (0.3mls) 3.5 mm from limbus in pseudophakic 
patients, 4mm in phakic patients, and then leave needle in situ and detach syringe. 
Intravitreal injection (0.425mls) from separate syringes of 
• Vancomycin (0.1ml) 
• Ceftazidime(0.25 mls) 
• Dex/placebo (0.1mls) 
 
Post injection, patients received topical ofloxacin (or equivalent fluoroquinolone) 
and topical dexamethasone hourly for 24 hours, then 2 hourly for two days, then 6 
hourly. Patients were reviewed daily in the ward and if initial therapy was deemed 
unsuccessful, patients were considered for repeat injection or vitrectomy.   
 
Criteria for repeat injection/vitrectomy (as per EVS recommendations): 
If all of the following were present, the injection was repeated: 
1. Visual acuity between counting fingers at 1 metre and perception of light 
2. Absent red reflex or increased opacification from presentation  
3. One of the following: 
• 1 mm increase in hypopyon 
• corneal ring infiltrate 
• worsening pain 
 
Patient Review: 
Patients were reviewed in the first 10 days and at 3 months. A separate 
endophthalmitis pack with prepared forms was designed and used to facilitate 
administrative issues, to standardise both treatment and record keeping (see 
addendum). 
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Outcomes: 
The primary outcome measure was the visual acuity using standard Snellen chart and 
visual acuity worse than 6/60 was graded using no perception of light, perception of 
light, hand movements, and count fingers at 1 metre. The visual acuity was then 
grouped into the following categories for comparison: 
Group 1: 6/6 – 6/18 
Group 2: 6/24-6/60 
Group 3: <6/60 
The visual acuities at presentation and at 3 months as well as the number of lines 
improvement on the Snellen chart were recorded. 
 
The secondary outcome measures were any adverse events and any side effects to 
the medication. 
 
Statistical Analysis:  
On completion of the study the pharmacy master records were collected and 
unmasked, and the data collected from the folders on a standard data form. 
 
Data was entered using a custom designed template in Microsoft Excel. 
 
Data was analysed using the statistical programme Stata Version 9.0. The analysis 
was on an intention to treat basis. The analysis was stratified according to the 
underlying cause of the endophthalmitis. Variables were described using means, 
medians and proportions, as appropriate. Bivariate comparisons were based on 
student t test (for means), Wilcoxon sum rank test (for medians), and Chi squared or 
Fisher’s exact test (for proportions). The main analysis focussed on describing the 
difference in the visual acuity outcome in the two groups. All statistical tests were 
two sided at a= 0.05. 
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CHAPTER 3 
RESULTS 
 
A total of 62 were patients were identified from the pharmacy master records 
between January 2001 and December 2005 who met the criteria and followed the 
protocols.  
 
 Diagram 1: Study Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
            
 
84 patients assessed 
for eligibility 
62 patients 
categorised 
32 Post Cataract: 
 
13 Bleb Related: 
17 Other: 
Randomised 
15 Placebo 
 
N= 14 
22 patients excluded: 
diagnosed as inflammatory 
records untraceable 
not meeting inclusion 
criteria 
Randomised 
Randomised 
17 Steroid 
 
9 Placebo 
 
4 Steroid  8 Placebo 
 
9 Steroid 
 
1 patient 
lost to 
follow up 
2 patients 
lost to 
follow up 
  1 patient 
lost to 
follow up 
1 patient  
admission va 
not recorded 
N= 17 N= 7 N= 4 N= 7 N= 8 
Final Analysis Final Analysis Final Analysis 
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Table 1 compares some of the characteristics of the two groups. There were no 
significant differences in any of the characteristics between the two groups.  
Table 1: Baseline Demographic 
 Steroid Placebo P Value 
Mean Age 59 (29-91) 61 (20-83) 
 
P >0.5 
Gender Male 11 (36%) 
Female 19 (63%) 
Male 18 (56%) 
Female 14 (54%) 
 
0.137 
Group: Post Cataract 
     Post Bleb 
Other 
17 (56%) 
4 (13%) 
9 (30%) 
15 (47%) 
9 (28%) 
8 (25%) 
 
0.974 
Systemic Co morbidity 
Yes 
No 
 
12 (40%) 
18 (60%) 
 
15 (47%) 
17 (53%) 
0.585 
Diabetes mellitus 
Yes 
No 
 
 
6 (20%) 
24 (80%) 
 
11 (34%) 
21 (66%) 
0.260 
Hypertension 
Yes 
No 
 
4 (13%) 
26 (87%) 
 
6 (19%) 
26 (81%) 
 
0.733 
HIV 
Yes 
No 
 
 
1 (3%) 
29 (97%) 
 
1 (3%) 
31 (97%) 
0.999 
Ocular Co morbidity 
Yes 
No 
 
10 (33%) 
20 (66%) 
 
15 (46 %) 
17 (54%) 
0.311 
Glaucoma 
Yes 
No 
 
 
5 (17%) 
25 (83%) 
 
11 (34%) 
21 (66%) 
0.150 
Diabetic Retinopathy 
Yes 
No 
 
 
5 (17%) 
25 (83%) 
 
2 (6%) 
30 (94%) 
0.249 
Cataract 
Yes 
No 
 
 
2 (7%) 
28 (93%) 
 
1 (3%) 
31 (97%) 
0.607 
ARMD 
Yes 
No 
 
 
0 
30 (100%) 
 
2 (6%) 
30 (94%) 
0.492 
Corneal Disease 
Yes 
No 
 
 
0 
30 (100%) 
 
1 (3%) 
31 (97%) 
0.999 
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Of the 62 patients, 30 received intravitreal steroid while 32 received intravitreal 
placebo (balanced salt solution). The largest subgroup was the post cataract surgery 
group (PC), which comprised 32 of the total 62 patients of which 15 received 
intravitreal placebo and 17 received intravitreal steroid.  There were 13 patients with 
bleb related endophthalmitis of which 4 patients received intravitreal steroid while 9 
patients received intravitreal placebo/balanced salt solution. Seventeen patients were 
classified as other: 8 trauma related with 4 receiving intravitreal steroids and 4 
receiving intravitreal placebo, 3 endogenous endophthalmitis of which 1 received 
intravitreal steroid and 2 received intravitreal placebo, 6 endophthalmitis following 
pars plana vitrectomy of which 4 received intravitreal steroids and 2 received 
intravitreal placebo. 
 
Graph 1 shows the breakdown of the subgroups within the steroid and placebo 
group. Unfortunately the numbers in the bleb related endophthalmitis and other 
groups are too small to derive statistical information within their respective groups, 
but they do contribute to the total number. 
 
Graph 1: Subgroups of Steroid and Placebo: 
15
17
9
4
8
9
0
2
4
6
8
10
12
14
16
18
Post Cataract Bleb Related Other
placebo
steroid
 
  
The primary outcome measured was the Snellen visual acuity on admission and at 3 
months. The number of lines improvement on the Snellen visual acuity chart was 
compared. This ranged from –3, i.e. lost 3 lines, to 9 i.e. gained 9 lines which 
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includes lines of No Perception of Light, Perception of Light, Hand movements and 
Count Fingers as well as the standard Snellen visual acuities. The mean 
improvement in the placebo group was 1.79 lines (-3 to 9) compared to the steroid 
group, which showed 2.76 (-3 to 9) lines of improvement (Student’s t test P=0.285). 
This is displayed as a histogram in graph 2. 
 
Graph 2: Snellen Chart No of lines of improvement Steroid vs Placebo 
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To compare visual outcomes between the 2 groups the Snellen visual acuities were 
also grouped into 3 categories according to the World Health Organisation 
classification: 
 Group 1: Good visual outcome 6/6 – 6/18 
 Group 2: Visually impaired: 6/24-6/60 
Group 3: Severe visual impairment and Blindness: less than 6/60 i.e. Count 
Fingers to No Perception of Light. 
P=0.285 
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This shows that of those patients who received intravitreal placebo, 88% had a visual 
acuity of less than 6/60 on admission. At 3 months 54% of these patients still had a 
visual acuity of less than 6/60. However, of patients who received intravitreal 
steroid, 82 % had a visual acuity of less than 6/60 on admission and at 3 months only 
43 % had a visual acuity of less than 6/60. In the placebo group 38% of patients had 
a final visual acuity of 6/18 or better while in the steroid group 43 % had a 3-month 
visual acuity of 6/18 or better. This is demonstrated in graphs 3 and 4. 
 
Graph 3 Visual Acuity of the Placebo group: Admission vs 3 month:  
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Graph 4 Visual Acuity of the Steroid group: Admission vs 3 month: 
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Graph 5 shows the comparison between the visual outcomes at 3 months of the total 
steroid and the total placebo group with a p value of 0.757 (Fishers exact test) 
 
Graph 5: 3-Month Visual Acuity comparison between Placebo vs Steroid 
 
Analysis of the post cataract group, consisting of 17 steroid patients and 15 placebo 
patients, was also conducted. Only 1 of the 3-month visual acuities in the placebo 
group was unavailable. The average lines improvement on the Snellen visual acuity 
chart was 2.7 (-3 to 9) for the placebo group compared to 4.1 (-3 to 9) for the steroid 
group (Student’s t test, p = 0.330). 
 
In the post cataract placebo group 93 % (14/15) presented with a visual acuity of less 
than 6/60 while at the 3 month visit only 46 % (6/13) had a visual acuity of less than 
6/60. In the post cataract steroid group, 76% (13/17) presented with a visual acuity 
of less than 6/60 and at the 3 month visit only 29 % (5/17) retained a visual acuity of 
less than 6/60. Of the placebo group 31% (4/13) had a good visual outcome with a 
visual acuity of 6/18 or better compared to the steroid group where 65% (11/17) had 
a visual acuity of 6/18 or better. This is shown in Graphs 6 and 7, while graph 8 
3 Month Snellen Visual Acuity
43
13
43
36
11
54
0
10
20
30
40
50
60
G roup	  1	  6/6-­‐6/18 G roup	  2	  6/24-­‐6/60 G roup	  3	  <6/60
pe
rc
en
ta
ge
	  o
f	  p
at
ie
nt
s
s teroid
placebo
P=0.757 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 23 
shows the 3-month comparison in Snellen category between the placebo and steroid 
patients in the post cataract subgroup, which shows a p value of 0.214 (Student’s t 
test). 
 
 Graph 6: Visual Acuity of the Placebo Post Cataract  on Admission vs 3-Month 
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Graph 7: Visual Acuity  of the Steroid Post Cataract on Admission vs 3-Month 
Steroid: Post Cataract Subgroup
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Graph 8: Post Cataract 3-Month Visual Acuity Placebo vs Steroid 
 
 
 
In the bleb related endophthalmitis group, 9 patients received intravitreal placebo, of 
whom 2 patients did not attend for follow up and 4 received intravitreal steroids.  
The mean number of lines improvement on the Snellen visual acuity chart for this 
placebo subgroup was 0.85 lines compared to the steroid subgroup, which was 1.25 
lines (Student’s t test, p=0.95). 
 
Of those patients who were classified as “other”: 
a) 8 were trauma related endophthalmitis of which 4 received steroid and 4  
    received placebo. 
b) 3 were due to endogenous endophthalmitis of which 1 received steroid and  
    2 received placebo. 
c) 6 were post pars plana vitrectomy of which 4 received steroid and 2  
    received placebo. 
The mean number of Snellen lines improvement in the “placebo: other” subgroup 
was 0.714 lines compared to the “steroid: other” subgroup which was 0.625 lines.  
(Student’s t test, p = 0.851) 
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The vitreous and aqueous taps yielded a 52.5 % positive culture rate. The most 
common organism cultured was Staphylococcus epidermidis, which was cultured in 
23% of all cases followed by Staphylococcus aureus and Streptococcus species 
(including pneumonia, mitis, oralis, constellatus, viridans, and intermedius). 
Unfortunately 5 results were lost with the installation of a new hospital information 
system. 
 
 Table 2 shows the organisms in each group.  
 
 
Table 2: Microbilogy Culture Results 
 
Organism Post Cataract Bleb Related Other 
Coagulase Neg. Staph. 7 4 3 
Staph. aureus 4 0 1 
Streptococcus species 5 2 1 
Bacillus 0 0 2 
Rhodococcus species 1 0 0 
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The only adverse events were 3 retinal detachments. All three patients were post 
cataract patients who received intravitreal steroids. One patient developed a total 
rhegmatogenous retinal detachment 5 days after the injection with a break noted at 
12h00. The injection site was recorded at 07h00. The patient had complicated 
cataract surgery with posterior capsular tear and anterior vitrectomy. An external 
retinal detachment repair was performed successfully but the 3-month visual acuity 
remained counting fingers. 
 
The second patient had undergone a lens washout for blunt traumatic cataract and 
developed a rhegmatogenous retinal detachment in the area of injection with severe 
proliferative retinopathy. A pars plan vitrectomy with insertion of silicone oil was 
performed, but the cornea decompensated and the vision remained hand movements 
at 3 months. 
 
The third patient also had complicated cataract surgery with posterior capsular tear 
and anterior vitrectomy. After intravitreal injection at 07h00 the visual acuity 
recovered to 6/9, but 6 months later developed an inferior rhegmatogenous retinal 
detachment with a break recorded at 04h00. 
 
No adverse reactions directly attributable to the intravitreal steroid were recorded. 
 
We also noted a delay in the presentation of the post cataract patients. The time 
between the surgery and the day of presentation was recorded and is shown in   
graph 9 
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Graph 9: Delay In Presentation of all Post Cataract Endophthalmitis 
 
Therefore 3 patients presented with a chronic form of endophthalmitis: 1 at 2 
months, 1 at 5 months and 1 at 6 months. The mean delay in presentation is 20.25 
days, but if the 3 chronic cases are removed then the mean delay is reduced to 8.6 
days and is displayed in graph 10. 
 
Graph 10: Delay In Presentation of Acute Post Cataract Endophthalmitis 
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Chapter 4 
Discussion 
 
The most important limitation of the study is the small sample size. Prior to the start 
of the study our department had experienced an increased incidence of all forms of 
endophthalmitis including referrals from secondary units. We planned to be able to 
recruit approximately 100 subjects over a five-year period. However, we were only 
able to recruit 62 subjects, of whom 32 had endophthalmitis following cataract 
surgery. There could have been merit in conducting a multi-centre study, to increase 
the sample size. 
  
A second weakness of our study is the difficulty we experienced in keeping accurate 
records in our busy understaffed clinic. Ideally, accurate records should have been 
kept on all patients considered for the trial and their reason for exclusion, as 
recommended by the Consort 23 statement. This does not affect the outcome in any 
way, but would improve the transparency of the reporting and thereby the confidence 
the reader has in evaluating the trial, especially in evaluating for any selection bias. 
The most common reason for exclusion was postoperative inflammation where the 
patient would be admitted for observation with intensive topical steroids and 
intravitreal injections ordered. However, if there was clinical improvement then the 
diagnosis was changed to post operative uveitis. Other exclusions included lost 
hospital records. A few patients who presented after hours were also excluded as 
they did not follow the correct protocols and subsequently were not randomised. The 
precise details of these patients were not recorded and should have been documented 
and displayed in flow diagram 1. 
 
A separate endophthalmitis trial pack (see appendix 1) was used on each patient to 
facilitate ease of record keeping, but in a few cases it replaced the master notes and 
some visual acuity records were missing. This highlights the need for any trial 
records to be separate from the main hospital record to ensure continuity of patient 
records, especially for medico-legal reasons. 
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A third weakness is the use of Snellen visual acuity charts, which is the only type of 
chart available in our clinics. Dr J. Holladay described the most accurate method of 
comparing visual acuities using the geometric equivalent as a logmar in order to 
compare geometric means etc. of different groups 24. The conversion tables (see 
appendix 2) are dependant on each line having the same number of letters such as on 
the EDTRS charts or Bailey –Lowe charts. Otherwise, each line would ideally 
require a separate conversion equation. However, he also points out that there is no 
logmar or geometric equivalent for visual acuity of Light Perception or No Light 
Perception, as they do not represent a measurable angle, but merely the detection or 
absence of a light stimulus. Thus he suggests that these patients are reported 
separately. In our study, this means that 22 (35 %) patients would be analysed 
separately, which would make the logmar analysis of the remaining visual acuities 
meaningless. 
 
A further difficulty encountered by all researchers interested in presumed bacterial 
endophthalmitis is the diagnosis. The gold standard is an appropriate vitreous or 
aqueous tap culture result. Our 52.5 % positive culture result is in keeping with the 
international standard, but this does always raise the question of the accuracy of 
differentiating infectious endophthalmitis from inflammatory uveitis especially in 
the early postoperative period. However if the sample size is adequate then this 
confounding variable should be neutralised by the successful randomisation. The 
baseline comparative demographics (Table 1) reveal no significant difference 
between the two groups which shows the success of the randomisation. We would 
hence expect this potential confounding variable to affect each group equally. 
 
Using the visual acuity at 3 months as a final acuity also has its drawbacks. Three 
months is a compromise between improving the follow up rate, which is traditionally 
very poor, and allowing sufficient time for the vision to finally stabilise and allowing 
for late complications to develop. It could be argued that the early anti-inflammatory 
effect of the steroids may mean quicker recovery but no difference in final vision if 
measured at either 6 or 12 months. Conversely, it may be argued that the placebo 
group may be at higher risk for long-term complications such as tractional retinal 
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detachments, which may be missed at the 3-month mark. The only way to know this 
would be to have a longer follow up period. 
 
The visual outcome in comparing the total steroid to the total placebo group showed 
no significant difference, which is in keeping with other studies. It did not show a 
detrimental effect, which has been previously shown by Shah's group 9. However 
these studies are usually limited to only post cataract endophthalmitis patients. In 
comparing the priority subgroup of the post cataract patients to other studies the 
results become more interesting. Firstly a beneficial trend was demonstrated despite 
the small numbers with the average number lines improvement being 4.1 in the 
steroid group compared to 2.7 with the same range (-3 to 9). Although the p value is 
only 0.330 due to the small numbers, this still appears clinically significant and is 
significantly different from Shah’s results of a non-randomised postoperative 
endophthalmitis study where they showed a reduced likelihood of a 3-line 
improvement in the steroid group 9. Our results are more in keeping with Gan’s 
result, which was also a randomised trial with 30 patients and showed a trend to 
better visual acuity in the steroid group 11. Thus the only two randomised trials of 
similar design both show a beneficial trend for the intravitreal steroid group in post 
cataract endophthalmitis patients. Similarly our study, as seen in Graph 8, shows a 
non-statistically significant trend towards better visual outcome for post cataract 
patients in the steroid group. 
 
The results of the bleb related endophthalmitis group and the other endophthalmitis 
group all show p values of nearly 1 due to the very low numbers in each group. The 
comparison of the number of lines improvement and the visual categories has no 
clinical significance. Therefore the role of intravitreal steroid in these clinical 
situations cannot be commented on. 
 
The 52.5% positive vitreous/aqueous tap culture rate is in keeping with published 
literature and the cultured organisms were as expected. The most common was 
Staphylococcus epidermidis, Staphylococcus aureus and Streptococcus species, 
which is in keeping with the literature. The 2 Bacillus species cultured were in 
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trauma related cases and the only unusual organism was the Rhodococcus species. 
This was cultured in a post cataract patient who presented on day 1 post surgery with 
a fulminant endophthalmitis that did not respond to treatment. The presenting visual 
acuity of no light perception did not improve. This organism is usually found in rural 
farming communities and the patient was a farm labourer.  
 
No adverse reactions or side effects were directly attributed to the intravitreal 
steroids. The only adverse events were the 3 rhegmatogenous retinal detachments. 
All 3 patients had complicated cataract surgery with posterior capsule rupture and 
vitreous loss. The retinal surgeons confirmed only 1 of the detachments as a definite 
consequence of the intravitreal injection with the site of the injection and the 
proliferative retinopathy anatomically correlating.  
 
It was of interest to note the delay in presentation. Traditionally 25 it is thought that 
there are 3 peaks of incidences in postoperative endophthalmitis: a day 2-4 peak of 
fulminant cases, days 5-7 less fulminant cases usually Staph. epidermidis and then 
the chronic cases usually presenting months after surgery. Therefore our mean delay 
of 20.25 days was surprising and even removing the 3 most chronic cases still left a 
mean delay of 8.6 days. This raises the question of why our patients present later 
than expected. Unfortunately the time between onset of symptoms and the time of 
presentation was not recorded which would have been helpful. We know in our 
setting the difficulty that patients have in attending the regional hospital, especially 
after hours with little or no public transport available. In addition the education and 
understanding of some of our patients might be limited. A further problem might be 
from the referring secondary hospital where cataract surgery is performed but there 
is no after hours ophthalmology service available and patients are meant to attend 
their regional hospital, but are generally ill informed of this. We know that any delay 
has a significant impact on visual outcome.  
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Chapter 5 
Conclusion 
 
The results of our study must be viewed in context of the small sample size. There is 
no statistically significant difference between the two groups. However, the patients 
who received intravitreal steroid showed a trend towards improved visual acuity 
compared with those who received intravitreal placebo, and this trend might be 
considered as clinically significant.  
 
This finding is the same as that of Gan and others, who also found a trend towards 
better visual outcome with intravitreal steroid. With the controversy that exists 
regarding the use of intravitreal steroids in the treatment of endophthalmitis, it is 
noteworthy that these two small randomized controlled trials show similar results. 
The results from these studies might be included in a future meta-analysis. The 
results highlight the need for a larger trial. 
 
We would recommend that consideration is given to including intravitreal 
dexamethasone in the treatment of post-operative endophthalmitis. It has been shown 
to be safe and most likely beneficial in two very similar studies. 
 
A further recommendation from our study is to highlight patient education regarding 
the symptoms of endophthalmitis and to encourage patients to seek medical attention 
as soon as possible if they develop symptoms of endophthalmitis. We have adapted 
our standard post-cataract surgery data sheets to include a tick box which both 
reminds the surgeon to highlight the dangers to the patient, as well as to document 
that the patient has been informed (see appendix). In addition, an improved referral 
system from our secondary level units performing high volume cataract surgery has 
also been implemented. 
 
 
Un
iv
rsi
ty 
of 
Ca
pe
 To
wn
 33 
Bibliography 
 
1. Ness T, Pelz K, Hansen LL. Endogenous endophthalmitis: microorganisms, 
disposition and prognosis. Acta Ophthalmol Scand. Dec 2007; 85(8): 852-6. 
 
2. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of 
experimentally induced endophthalmitis. Arch Ophthalmol. 1974 Aug; 92(2):149-54.  
 
3. Kamalarajah S, Silvestri G et al. Surveillance of endophthalmitis following 
cataract surgery in the UK. Eye 2004 Jun; 18(6): 580-7. 
 
4. Okhravi N, Towler HM et al. Assessment of a standard treatment protocol on 
visual outcome following presumed bacterial endophthalmitis. Br. J. Ophthalmol. 
1997; 81: 719-25. 
 
5. Lalwani GA, Flynn HW Jr. et al. Acute-onset endophthalmitis after clear corneal 
cataract surgery (1996-2005). Clinical features, causative organisms, and visual 
acuity outcomes. Ophthalmology. 2008 Mar; 115(3): 473-6. 
 
6. Chaudhry NA et al. A cluster of patients with acute-onset endophthalmitis 
following cataract surgery. Ophthalmic Surg Lasers Imaging. 2005 May-Jun; 36(3): 
205-10.  
 
7. Elder MJ, Morlet N. Clinical controversy. Clin and Exp Ophthalmol (2002); 30: 
394-398. 
 
8. Das T, Jalali S et al. Intraviteral dexamethasone in exogenous bacterial 
endophthalmitis: results of a prospective randomized study. Br J. Ophthalmol 1999; 
83: 1050 –55. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 34 
 
9. Shah GK et al. Visual outcomes following the use of intravitreal steroids in the 
treatment of postoperative endophthalmitis. Ophthalmology. 2000 Mar; 107(3): 486-
489. 
 
10. Pollack JS et al. Failure of intravitreal dexamethasone to diminish inflammation 
or retinal toxicity in an experimental model of Bacillus cereus endophthalmitis. Curr 
Eye Res. 2004 Oct-Nov; 29(4-5): 253-9. 
 
11. Gan IM et al. Intravitreal dexamethasone as adjuvant in the treatment of 
postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin 
Exp Ophthalmol. 2005 Dec; 243 (12): 1200-5. 
 
12. Pathengay A et al.  Intravitreal triamcinolone acetonide in the management of 
exogenous bacterial endophthalmitis. Am J Ophthalmol. 2006 May;141(5):938-40. 
 
13. Ermis SS et al. Effects of intravitreal moxifloxacin and dexamethasone in 
experimental Staphylococcus aureus endophthalmitis. Curr Eye Res. 2007 Apr; 
32(4): 337-44. 
 
14. Rehak M et al.  [Primary vitrectomy with intraocular antibiotic application in 
postoperative endophthalmitis]. Ophthalmologe. 2007 Nov; 104(11): 958-64.  
 
15. Saleh M et al. [Advantages of corticosteroids in managing acute bacterial 
postoperative endophthalmitis.] J Fr Ophtalmol. 2008 Oct; 31(8): 825-33. 
 
16. De Kaspar HM et al. Effects of intravitreal corticosteroid in the treatment of 
Staphylococcus aureus-induced experimental endophthalmitis. Retina. 2008 Feb; 
28(2): 326-327. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 35 
 
17. Liu F et al. The efficacy of intravitreal vancomycin and dexamethasone in the 
treatment of experimental bacillus cereus endophthalmitis. Curr Eye Res. 2008 Sep; 
33(9): 761-8.  
 
18. Kwak HW et al. Evaluation of the retinal toxicity and pharmacokinetics of 
dexamethasone after intravitreal injection. Arch Ophthalmol. 1992 Feb;110(2): 259-
66. 
 
19. Smith MA et al. Effects of intravitreal dexamethasone on concentration of 
intravitreal vancomycin in experimental methicillin-resistant Staphylococcus 
epidermidis endophthalmitis. Antimicrob Agents Chemother. 1991 Jul; 35(7):1298-
302.  
 
 
20. Park SS et al. Intravitreal dexamethasone effect on intravitreal vancomycin 
elimination in endophthalmitis. Arch Ophthalmol. 1999 Aug; 117(8): 1058-62.  
 
21. Gan IM et al.  Effect of intravitreal dexamethasone on vitreous vancomycin 
concentrations in patients with suspected postoperative bacterial endophthalmitis. 
Graefes Arch Clin Exp Ophthalmol. 2005 Nov; 243(11): 1186-9. 
 
22. Doft BH et al. The endophthalmitis vitrectomy study. Arch Ophthalmol. 1991 
Apr; 109(4): 487-9. 
 
23. Moher et al. The CONSORT statement: revised recommendations for improving 
the quality of reports of parallel-group randomised trials. The Lancet. 2001 April; 
357: 1191-94. 
 
Un
iv
rsi
ty 
of 
Ca
pe
 To
wn
 36 
24. Jack T.Holladay. Guest Editorial: Visual acuity measurements. J Cataract 
Refract Surg. 2004 February; 30: 287-290. 
 
25. Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual 
outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol. Dec 1996; 
122(6): 830-46. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 37 
Acknowledgements: 
 
Drs J. Richards and T. Pollock who designed and initiated the study. 
 
Professor C Cook for supervising the dissertation. 
 
Professor Landon Myers for the statistical analysis. 
 
All the hardworking Registrars, Consultants and Nursing Staff of the Ophthalmology 
Division without whose assistance this would not have been possible. 
 
 
 
 
 
 
 
 
 Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Changes	  to	  Dissertation:	  18/11/2009
	  Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
